<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ESTRADIOL WITH NOMEGESTROL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ESTRADIOL WITH NOMEGESTROL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#constituents" data-toggle="tab">Constituants</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraceptive</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 active tablet daily for 24 days, followed by 1 inactive tablet daily for 4 days, to be started on day 1 of cycle with first active tablet (withdrawal bleeding occurs when inactive tablets being taken); subsequent courses repeated without interval.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>

      <section class="tab-pane" id="constituents">
        <h2>Constituents</h2>

        <p>
          <a href="./PHP94655.html">estradiol</a>
        </p>
      </section>


      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin- Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), liver tumours.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>gallstones</li>
            <li>heart disease associated with pulmonary hypertension</li>
            <li>heart disease associated with risk of embolus</li>
            <li>history during pregnancy of cholestatic jaundice</li>
            <li>history during pregnancy of chorea</li>
            <li>history during pregnancy of pemphigoid gestationis</li>
            <li>history during pregnancy of pruritus</li>
            <li>history of breast cancer (but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable)</li>
            <li>history of haemolytic uraemic syndrome</li>
            <li>migraine with aura</li>
            <li>multiple risk factors for arterial disease</li>
            <li>multiple risk factors for venous thromboembolism</li>
            <li>personal history of arterial thrombosis</li>
            <li>personal history of venous thrombosis</li>
            <li>sclerosing treatment for varicose veins</li>
            <li>severe risk factors for arterial disease</li>
            <li>severe risk factors for venous thromboembolism</li>
            <li>systemic lupus erythematosus with (or unknown) antiphospholipid antibodies</li>
            <li>transient cerebral ischaemic attacks without headaches</li>
            <li>undiagnosed vaginal bleeding</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Gallstones, systemic lupus erythematosus,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal cramps, absence of withdrawal bleeding, amenorrhoea after discontinuation, breast enlargement, breast secretion, breast tenderness, cervical erosion, changes in libido, changes in lipid metabolism, changes in vaginal discharge, chloasma, chorea, contact lenses may irritate, depression, fluid retention, headache, hepatic tumours, hypertension, irritability, leg cramps, liver impairment, nausea, nervousness, photosensitivity, reduced menstrual loss, skin reactions, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB), visual disturbances, vomiting, &#8216;spotting&#8217; in early cycles,
              </p>
        
        
            <section class="advice">
                <h3>Breast cancer</h3>
              <p>There is a small increase in the risk of having breast cancer diagnosed in women taking the combined oral contraceptive pill; this relative risk may be due to an earlier diagnosis. In users of combined oral contraceptive pills the cancers are more likely to be localised to the breast. The most important factor for diagnosing breast cancer appears to be the age at which the contraceptive is stopped rather than the duration of use; any increase in the rate of diagnosis diminishes gradually during the 10 years after stopping and disappears by 10 years.</p>
            </section>
            <section class="advice">
                <h3>Cervical cancer</h3>
              <p>Use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years. The risk of cervical cancer with transdermal patches and vaginal rings is not yet known.</p><p>The possible small increase in the risk of breast cancer and cervical cancer should be weighed against the protective effect against cancers of the ovary and endometrium.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Each tablet should be taken at approximately same time each day; if delayed, contraceptive protection may be lost.</p><p>
            <i>Zoely</i>
            <tm tmtype="reg"/>
            <i> (every day (ED) combined (monophasic) preparation)</i>, 1 <i>active</i> tablet daily for 24 days, followed by 1 <i>inactive</i> tablet daily for 4 days, starting on day 1 of cycle with first <i>active</i> tablet; subsequent courses repeated without interval (withdrawal bleeding occurs when <i>inactive</i> tablets being taken).</p>
            </section>
            <section class="directionsForAdministration">
                <h3>Changing to combined preparation containing different progestogen</h3>
              <p>If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start the first active tablet of new brand immediately.</p><ul>
            <li>Changing to <i>Qlaira</i>
            <tm tmtype="reg"/>: start the first active <i>Qlaira</i>
            <tm tmtype="reg"/> tablet on the day after taking the last active tablet of the previous brand</li>
            <li>Changing to <i>Zoely</i>
            <tm tmtype="reg"/>: start the first active <i>Zoely</i>
            <tm tmtype="reg"/> tablet on the day after taking the last active tablet of the previous brand or, at the latest, the day after the tablet-free or inactive tablet interval of the previous brand</li>
            <li>Changing from <i>Qlaira</i>
            <tm tmtype="reg"/> or <i>Zoely</i>
            <tm tmtype="reg"/>: start the new brand after taking the last active tablet; if the inactive tablets are taken before starting new brand, additional precautions (barrier methods) should be used during first 7 days of taking the new brand</li>
            </ul><p>Each tablet should be taken at approximately same time each day; if delayed, contraceptive protection may be lost.</p>
            </section>
            <section class="directionsForAdministration">
                <h3>Changing from progestogen-only tablet</h3>
              <p>If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start new brand immediately, additional precautions (barrier methods) necessary for first 7 days.</p><p>Changing to <i>Qlaira</i>
            <tm tmtype="reg"/>: start any day, additional precautions (barrier methods) necessary for first 9 days.</p>
            </section>
            <section class="directionsForAdministration">
                <h3>Secondary amenorrhoea (exclude pregnancy)</h3>
              <p>Start any day, additional precautions (barrier methods) necessary during first 7 days (9 days for <i>Qlaira</i>
            <tm tmtype="reg"/>).</p>
            </section>
            <section class="directionsForAdministration">
                <h3>After childbirth (not breast-feeding)</h3>
              <p>Start 3 weeks after birth (increased risk of thrombosis if started earlier); later than 3 weeks postpartum additional precautions (barrier methods) necessary for first 7 days (9 days for <i>Qlaira</i>
            <tm tmtype="reg"/>).</p>
            </section>
            <section class="directionsForAdministration">
                <h3>After abortion or miscarriage</h3>
              <p>Start same day.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
                <h3>Missed dose</h3>
              <p>A missed pill for a patient taking <i>Zoely</i>
            <tm tmtype="reg"/> is one that is 12 hours or more late; for information on how to manage missed pills in women taking <i>Zoely</i>
            <tm tmtype="reg"/>, refer to product literature.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Travel</h3>
              <p>Women taking oral contraceptives or using the patch or vaginal ring are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Diarrhoea and vomiting</h3>
              <p>Vomiting and persistent, severe diarrhoea can interfere with the absorption of combined oral contraceptives. If vomiting occurs within 2 hours of taking a combined oral contraceptive another pill should be taken as soon as possible. In cases of persistent vomiting or severe diarrhoea lasting more than 12 hours in women taking <i>Zoely</i>
            <tm tmtype="reg"/>, refer to product literature.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
            arterial disease
          </li>
          <li>
            Crohn&#8217;s disease
          </li>
          <li>
            family history of hypertriglyceridaemia (increased risk of pancreatitis)
          </li>
          <li>
            gene mutations associated with breast cancer (e.g. BRCA 1)
          </li>
          <li>
            history of severe depression especially if induced by hormonal contraceptive
          </li>
          <li>
            hyperprolactinaemia (seek specialist advice)
          </li>
          <li>
            inflammatory bowel disease
          </li>
          <li>
            migraine
          </li>
          <li>
            personal history of hypertriglyceridaemia (increased risk of pancreatitis)
          </li>
          <li>
            risk factors for venous thromboembolism
          </li>
          <li>
            sickle-cell disease
          </li>
          <li>
            undiagnosed breast mass
          </li>
        </ul>
        <ul>
          <li>
            <p>There is an increased risk of venous thromboembolic disease in users of combined hormonal contraceptives particularly during the first year and possibly after restarting combined hormonal contraceptives following a break of four weeks or more. This risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100&#8239;000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors, such as obesity. The risk also varies depending on the type of progestogen.</p><p>Provided that women are informed of the relative risks of venous thromboembolism and accept them, the choice of oral contraceptive is for the woman together with the prescriber jointly to make in light of her individual medical history and any contra-indications.</p><p>Combined hormonal contraceptives also slightly increase the risk of <i>arterial</i> thromboembolism; however, there is no evidence to suggest that this risk varies between different preparations.</p><fig>
        <title>Combined Hormonal Contraception and Risk of Venous Thromboembolism</title>
        <simpletable>
        <sthead>
        <stentry>Progestogen in Combined Hormonal Contraceptive</stentry>
        <stentry>Estimated incidence per 10,000 women per year of use</stentry>
        </sthead>
        <strow>
        <stentry>Non-pregnant, not using combined hormonal contraception</stentry>
        <stentry>2</stentry>
        </strow>
        <strow>
        <stentry>Levonorgesterol <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Norgestimate <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Norethisterone <sup>1</sup>
        </stentry>
        <stentry>5&#8211;7</stentry>
        </strow>
        <strow>
        <stentry>Etonogestrel <sup>1</sup>
        </stentry>
        <stentry>6&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Norelgestromin <sup>1</sup>
        </stentry>
        <stentry>6&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Gestodene <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Desogestrel <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Drospirenone <sup>1</sup>
        </stentry>
        <stentry>9&#8211;12</stentry>
        </strow>
        <strow>
        <stentry>Dienogest <sup>2</sup>
        </stentry>
        <stentry>Not known&#8212;insufficient data</stentry>
        </strow>
        <strow>
        <stentry>Nomegestrol <sup>2</sup>
        </stentry>
        <stentry>Not known&#8212;insufficient data</stentry>
        </strow>
        <strow outputclass="tfoot">
        <stentry>
        <sup>1</sup>:-Combined with ethinylestradiol <sup>2</sup>:-Combined with estradiol</stentry>
        </strow>
        </simpletable>
        </fig>
          </li>
          <li>
            <p>Use with <b>caution</b> if any of following factors present but <b>avoid</b> if two or more factors present:</p><ul>
        <li>
        <i>family history of venous thromboembolism</i> in first-degree relative aged under 45 years (avoid contraceptive containing desogestrel or gestodene, <i>or</i> avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));</li>
        <li>
        <i>obesity</i>&#8212;body mass index &#8805;30&#8239;kg/m<sup>2</sup> (avoid if body mass index &#8805;35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li>
        <li>
        <i>long-term immobilisation</i> e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);</li>
        <li>
        <i>history of superficial thrombophlebitis;</i>
        </li>
        <li>
        <i>age</i> over 35 years (avoid if over 50 years);</li>
        <li>
        <i>smoking.</i>
        </li>
        </ul>
          </li>
          <li>
            <p>Use with <b>caution</b> if any one of following factors present but <b>avoid</b> if two or more factors present:</p><ul>
        <li>
        <i>family history of arterial disease</i> in first degree relative aged under 45 years (avoid if atherogenic lipid profile);</li>
        <li>
        <i>diabetes mellitus</i> (avoid if diabetes complications present);</li>
        <li>
        <i>hypertension</i>&#8212;blood pressure above <i>systolic 140&#8239;mmHg</i> or <i>diastolic 90&#8239;mmHg</i> (avoid if blood pressure above <i>systolic 160&#8239;mmHg</i> or <i>diastolic 95&#8239;mmHg</i>); (In adolescents, avoid if blood pressure very high);</li>
        <li>
        <i>smoking</i> (avoid if smoking 40 or more cigarettes daily);</li>
        <li>
        <i>age</i> over 35 years (avoid if over 50 years);</li>
        <li>
        <i>obesity</i> (avoid if body mass index &#8805;35&#8239;kg/m<sup>2</sup> unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);</li>
        <li>
        <i>migraine without aura</i> (avoid if <i>migraine with aura</i> (focal symptoms), <i>or</i> severe migraine frequently lasting over 72 hours despite treatment, <i>or</i> migraine treated with ergot derivatives).</li>
        </ul>
          </li>
          <li>
            <p>Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).</p><p>Combined hormonal contraceptives should be stopped (pending investigation and treatment), if serious neurological effects occur, including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body.</p>
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ESTRADIOL WITH NOMEGESTROL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP92412"><a href="../medicinalForm/PHP92412.html" data-target="#PHP92412" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
